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The origin of cardiac markers can be traced back to the
mid-1950s with the ﬁnding that aspartate aminotransferase
was useful in the detection of acute myocardial infarction
(AMI) (1). Since then, there has been a steady stream of
improvements of laboratory tests that aid in the diagnosis of
AMI in terms of the discovery of new markers and analytic
reﬁnements of assays used to measure them. Aspartate
aminotransferase as a cardiac marker was pushed aside by
creatine kinase (CK) and CK-MB (2), which continue to be
available in many hospitals today but are slowly being phased
out in favor of cardiac troponin. The ﬁrst troponin assaysSee page 1242were cleared by the U.S. Food and Administration in 1994,
but the “troponin era” can be traced to the redeﬁnition of
AMI by a joint committee of European and American
cardiologists (3). Troponin was identiﬁed as the preferred
serologic biomarker for acute coronary syndrome (ACS).
Over the next dozen years, troponin assays have improved
with respect to analytic sensitivity, assay reproducibility,
freedom from interferences, and availability of point-of-care
testing platforms. In addition, there has been an evolution of
strategies that deﬁne the optimum cutoff concentrations.
These assay modiﬁcations have led to further reﬁnements in
the guidelines in 2007 (4) and again in 2012 (5).
With each generation of troponin assays has come the
reduction of upper limit of normal and cutoff concentra-
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patients with a mild increase in troponin in the context of
unstable angina were at risk for future adverse cardiac events,
the cutoffs were lowered to the 99th percentile of a healthy
population. The ﬁrst-generation assays were insufﬁciently
sensitive to detect troponin in the sera of health subjects.
Therefore, the 99th percentile limit was set at the assay’s
limit of detection, for example, 0.50 ng/ml. With current-
generation high-sensitivity assays, the majority of healthy
subjects have measurable troponin concentrations (i.e., above
the limit of detection). This has further reduced the upper
limit of normal to 0.010 ng/ml with the highest sensitive
troponin assay currently available (6).
The implementation of improved troponin assays and the
lowering of the 99th percentile have resulted in considerable
confusion among emergency department (ED) physicians
and cardiologists. Unlike CK-MB, for which cutoff con-
centrations were established to separate unstable angina
from AMI, the use of the 99th percentile has resulted in
detecting many more cases of increased troponin that are
caused by a nonischemic origin. If one considers that
troponin is a marker of myocardial injury, then these high
results are not false indications of AMI but are true positives
resulting from myocardial damage. Positive results are seen
in patients with renal failure, heart failure, venous throm-
bosis, and many other diseases (7). The key in separating
ischemic and nonischemic causes in patients with increased
troponin is serial testing. The demonstration of a signiﬁcant
increase (or decrease) in troponin is indicative of an acute
disease process, as opposed to an unchanging troponin result
that is seen in chronic disease states.
Advancement in biomarker technology and the concom-
itant requirement to redeﬁne safe clinical thresholds parallel
the history of progress in other essential testing procedures
in cardiology. Echocardiography, which like troponin assays
is safe, relatively inexpensive, and readily available in EDs
and primary care settings, is an example. As echocardio-
graphic transducer and system technology have advanced,
the range of disorders that it can detect and the accuracy of
those diagnoses have increased with the quality of the
images. With each signiﬁcant jump in image quality, how-
ever, a repetitive pattern occurs: With improvements in
sensitivity, details that were previously obscured may
become apparent. Until the diagnostic bar is reset, normal
ﬁndings may be misinterpreted as pathological. As a result,
on a regular and recurring basis the entire spectrum of
ultrasound-interpreting physicians must go through a new
learning curve to accommodate the changes in the data
quality. In some cases, the diagnoses most affected are those
with great clinical impact, just as ACS is for troponin assays.
In the case of echocardiography, recent improvements in
near-ﬁeld resolution with transthoracic echocardiographic
imaging have been accompanied by an increase in clinical
uncertainty regarding the right ventricular anterior wall,
which was previously difﬁcult to see in such detail. Because
right ventricular dysplasia is a risk for arrhythmias and
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“normal” right ventricular anatomy may lead to additional
testing and clinical concerns for the provider and patient.
With this issue, just as with prior episodes of data-quality
resets, time and accumulation of experience will likely
restore the impaired speciﬁcity of the test that follows these
quantum leaps in imaging sensitivity as users become reca-
librated to its use.
In this issue of the Journal, Cullen et al. (8) used a high-
sensitivity troponin I assay with a cutoff of 26.2 ng/l. This
assay is not yet cleared by the Food and Drug Administra-
tion, but it is available in Europe and Asia. They showed
that in patients with a Thrombolysis In Myocardial Infarc-
tion risk score of 1 (i.e., low risk), the clinical sensitivity
and negative predictive value for AMI were 99.2% and
99.7% respectively, when blood was sampled at the time of
ED admission and 2 h thereafter (8). In the Online
Appendix 6 of the article by Cullen et al.(8), the three
missed patients are described in more detail. One (Patient
#3) or maybe two patients (add Patient #1) did not meet
many experts’ criteria for a change in troponin, meaning that
although they might have myocardial injury, it was not
due to an AMI. With the exclusion of those patients, the
negative predictive value would increase to 99.9%. These
authors suggested that approximately 40% of patients
admitted with suspected ACS can be safely discharged with
a minimal risk for returning within 30 days with a major
adverse cardiac event. Can high-sensitivity troponin assays
be used to “rule out” ACS and facilitate early discharge?
From the ED perspective, chest pain is the second most
common symptom and the leading cost of malpractice dollars
spent. The historically conservative approach to avoid
missing anyone with a potential ACS has led clinicians
to admit many more patients than are subsequently found
to have disease. This further affects ED crowding and
boarding, which are associated with adverse outcomes for
both patients with and without ACS (9). High-sensitivity
troponin assays now allow us to detect this marker in some
asymptomatic subjects without an acute medical symptom.
By deﬁnition, a high-sensitivity assay can detect troponin in
normal volunteers. When used in the ED setting, an
“increased” or measurable high-sensitivity troponin value
does not mean that the patient has ACS or even that
admission is warranted. Many groups are currently trying to
determine when a positive troponin is not due to ACS and
how best to manage these patients.It still remains to be demonstrated prospectively that
patients discharged early from theEDhave longer-term safety
comparable to those receiving more conventional screening.
Both early and conventional discharge strategies often rely
on additional diagnostic evaluation with stress testing or at
follow-up outpatient visits. This type of evaluation will
continue to be required to answer the “if not cardiac in
etiology, then what?” question that must always accompany
any episode of chest pain. Abnormal high-sensitivity troponin
values, even if the trend does not suggest acute ischemia, may
underscore the importance of such follow-up testing and
targeted attention from primary care providers.
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